NeuroScientific Biopharmaceuticals Limited (NSB.AX)

0.0400 +0.0010 (+2.56%) At close: 03:26PM AEDT

NeuroScientific Biopharmaceuticals Limited

85 Forrest Street
Suite 5
Cottesloe, WA 6011
Australia
61 8 6382 1805
https://www.neuroscientific.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Anthony James Keating	Executive Director	158.83k	N/A	N/A
Mr. Christopher Bryan James Achurch B.Com., C.A.	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

NeuroScientific Biopharmaceuticals Limited engages in the research and development of novel peptide-based pharmaceutical products. The company is involved in the development of therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative Alzheimer's disease, multiple scierosis, glaucoma, optic nerve atrophy, and other diseases. The company was incorporated in 2002 and is based in Cottesloe, Australia.

Corporate governance

NeuroScientific Biopharmaceuticals Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.